ALYFTREK's Patent Shield Extended: FDA Calls for Challenges
Published Date: 2/13/2026
Notice
Summary
The FDA has set the official review period for ALYFTREK, a new drug, so its patent holder can apply for extra patent time. This helps the company protect their invention longer, potentially delaying generic competition and affecting drug prices. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they have until April or August 2026 to speak up.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Drug patent review period set
The FDA found that ALYFTREK had a regulatory review period of 5,335 days (5,102 days testing phase and 233 days approval phase). The testing phase began May 15, 2010; the new drug application was submitted May 2, 2024; and FDA approved the application on December 20, 2024. The applicant is seeking 1,826 days of patent term extension, and FDA’s determination establishes the maximum potential length of a patent extension.
Public comment and petition windows
Anyone who thinks the published dates are wrong can submit comments requesting a redetermination by April 14, 2026. Any interested person may petition FDA about whether the applicant acted with due diligence during the regulatory review period by August 12, 2026. Instructions for electronic and written submissions are provided in the notice.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13820 — Determination That TOVALT ODT (Zolpidem Tartrate) Orally Disintegrating Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that TOVALT ODT tablets (5 mg and 10 mg) weren’t taken off the market because of safety or effectiveness problems. This means generic drug makers can now apply to sell their own versions, making it easier and cheaper for people who need this sleep aid. If approved, more affordable options could hit the shelves soon, helping patients and saving money.
2026-13778 — Medical Device User Fee Amendments; Public Meeting; Request for Comments
The FDA is planning a public meeting on August 5, 2026, to talk about renewing fees that medical device makers pay to help speed up device reviews from 2028 to 2032. This affects companies making medical devices and could impact how much they pay and how fast their products get approved. The current fee program ends in September 2027, so the FDA wants your thoughts before finalizing new rules and fees.
2026-13716 — New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of Sponsor
The FDA just updated the rules for new animal drugs, approving several new and generic medicines for pets and farm animals from early 2026. These changes help keep animal treatments safe and effective, and the updates take effect right away on July 7, 2026. If you’re a drug maker or animal caretaker, these approvals and sponsor changes could impact what medicines are available and when.
2026-13534 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Administrative Practices and Procedures; Formal Hearings
The FDA is asking for public feedback on how it collects information for formal hearings and administrative rules. This affects businesses and people who interact with the FDA, with no new costs but a chance to improve paperwork processes. Comments are due by August 5, 2026, so don’t miss your chance to weigh in!
2026-13616 — Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
The FDA is officially pulling the plug on 34 drug approvals because the companies stopped selling these medicines. This change kicks in on August 5, 2026, and it mainly affects drug makers like Endo Operations and Pfizer. No money penalties here—just a clean break, but companies can ask to reapply if they want to bring the drugs back.
Previous / Next Documents
Previous: 2026-02967 — Agency Information Collection Activities: Submission for OMB Review; Comment Request
The Centers for Medicare & Medicaid Services (CMS) wants your thoughts on their plan to keep collecting important info from the public. If you or your group deal with Medicare or Medicaid, this affects you! You’ve got until March 16, 2026, to share your ideas on how to make this process easier and better, with no new costs announced.
Next: 2026-02969 — Notice of Petition for Extension of Waiver of Compliance
The Association of American Railroads (AAR) asked the Federal Railroad Administration (FRA) to extend a break from some air brake maintenance rules for certain electronic brake systems. This means trains using these brakes can wait longer between checkups, thanks to a strong safety record. If you want to share your thoughts, make sure to comment by March 16, 2026!